375 related articles for article (PubMed ID: 28071837)
1. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series.
Lund T; Thomsen SF
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28071837
[TBL] [Abstract][Full Text] [Related]
2. A Case Series of Patients With Psoriasis Exposed to Biologic Therapy During Pregnancy: The BIOBADADERM Register and a Review of the Literature.
Echeverría-García B; Nuño-González A; Dauden E; Vanaclocha F; Torrado R; Belinchón I; Pérez-Zafrilla B;
Actas Dermosifiliogr; 2017 Mar; 108(2):168-170. PubMed ID: 27765165
[No Abstract] [Full Text] [Related]
3. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
4. Biologics exposure during pregnancy and breastfeeding in a psoriasis patient.
Mugheddu C; Atzori L; Lappi A; Murgia S; Rongioletti F
Dermatol Ther; 2019 May; 32(3):e12895. PubMed ID: 30958637
[TBL] [Abstract][Full Text] [Related]
5. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
Takahashi N; Noda S; Taniguchi T; Adachi M
Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
[TBL] [Abstract][Full Text] [Related]
6. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
7. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
8. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
Sorensen EP; Fanucci KA; Saraiya A; Volf E; Au SC; Argobi Y; Mansfield R; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):893-8. PubMed ID: 26267736
[TBL] [Abstract][Full Text] [Related]
9. The Safety Profiles of Adalimumab, Infliximab, Etanercept, Secukinumab and Ustekinumab in Psoriasis - A 30-month Observational Cohort Prospective Study of Adverse Events in Biologic Therapy.
Paluch Z; Marques E; Boháč P; Zemková K; Hercogová J
Acta Dermatovenerol Croat; 2024 Mar; 32(1):7-16. PubMed ID: 38946182
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab in patients previously treated with TNFα inhibitors: a real-life study.
Pinheiro RR; Duarte B; Ferreira A; Cabete J
Eur J Dermatol; 2018 Feb; 28(1):89-91. PubMed ID: 29400282
[No Abstract] [Full Text] [Related]
11. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation.
Maloney NJ; Hisaw LD; Worswick S
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 29034547
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy during Ustekinumab Treatment for Severe Psoriasis.
Rocha K; Piccinin MC; Kalache LF; Reichert-Faria A; Silva de Castro CC
Dermatology; 2015; 231(2):103-4. PubMed ID: 25790947
[TBL] [Abstract][Full Text] [Related]
13. Drug survival of biologic treatments in psoriasis: a systematic review.
No DJ; Inkeles MS; Amin M; Wu JJ
J Dermatolog Treat; 2018 Aug; 29(5):460-466. PubMed ID: 29076754
[TBL] [Abstract][Full Text] [Related]
14. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis.
Alsenaid A; Prinz JC
J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):488-90. PubMed ID: 25413895
[No Abstract] [Full Text] [Related]
15. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab.
Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
J Dermatolog Treat; 2019 Feb; 30(1):40-44. PubMed ID: 29676599
[TBL] [Abstract][Full Text] [Related]
16. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
17. Severe dilated cardiomyopathy induced by adalimumab and ustekinumab.
Membrillo de Novales FJ; Ávila Jiménez A; Merino Meléndez L; Torres León J; López Soberón E; Fe Marqués A; Pérez Mochales JF
J Clin Rheumatol; 2015 Apr; 21(3):171-3. PubMed ID: 25807103
[No Abstract] [Full Text] [Related]
18. Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis.
Yanaba K; Umezawa Y; Honda H; Sato R; Chiba M; Kikuchi S; Asahina A; Nakagawa H
J Dermatol; 2016 Apr; 43(4):443-4. PubMed ID: 26662275
[No Abstract] [Full Text] [Related]
19. Switching biologics in severe pediatric psoriasis: a retrospective analysis.
Ramos Pinheiro R; Diamantino F; Cabete J; Brasileiro A; Baptista J; Lopes MJP
Int J Dermatol; 2017 Dec; 56(12):1461-1464. PubMed ID: 28960270
[No Abstract] [Full Text] [Related]
20. The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: a retrospective study.
Shaaban D; Al-Mutairi N
J Dermatolog Treat; 2018 Feb; 29(1):3-7. PubMed ID: 27881030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
